| Drug Name |
Gefitinib |
| Drug ID |
BADD_D01008 |
| Description |
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. |
| Indications and Usage |
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EB01 |
| DrugBank ID |
DB00317
|
| KEGG ID |
D01977
|
| MeSH ID |
D000077156
|
| PubChem ID |
123631
|
| TTD Drug ID |
D09XZB
|
| NDC Product Code |
61200-002; 65344-0029; 54245-1359; 60505-4512; 69339-168; 50742-366; 67184-0531; 0310-0482; 53104-7700; 63850-8070; 0480-4053; 68554-0060; 73377-128; 54893-0036 |
| UNII |
S65743JHBS
|
| Synonyms |
Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839 |
